Trials / Completed
CompletedNCT01846481
A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse
A Randomized, Double-blind, Placebo-controlled, Dose of RBP-8000 Following IV Cocaine to Evaluate the Pharmacokinetics Parameters of RBP-8000 and Cocaine and to Assess the Effects of Drug on Cocaine-induced Physiologic and Behavioral Effects in Cocaine Abusing Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Indivior Inc. · Industry
- Sex
- All
- Age
- 21 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, 4-sequence, 2-period, double-blind, placebo controlled study in male and female subjects with an American Psychiatric Association Diagnostic and Statistical Manual DSM-IV-TR diagnosis of cocaine abuse.
Detailed description
There will be a 28-day screening period with eligible subjects remaining resident in the clinic from the evening before Day -1 up and until the morning of Day 9. On the morning of Day 1, a 50 mg intravenous (IV) infusion of cocaine will be administered over 10 minutes to all subjects. If none of the stopping criteria were met and no intervening safety concerns, subjects will be randomized to one of the treatment sequences on Day 3. On dosing days, Day 3 and Day 6, subjects will have fasted at least 8 hours before dosing of cocaine and either RBP-8000 200 mg, RBP-8000 100 mg or matching placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RBP-8000 100 mg | RBP-8000 100 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6 |
| DRUG | Placebo | IV infusion of Placebo administered 1 minute after cocaine infusion on either day 3 or 6. |
| DRUG | Cocaine | 50 mg intravenous (IV) dose of cocaine administered over 10 minutes on Days 1, 3 and 6. |
| DRUG | RBP-8000 200 mg | RBP-8000 200 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6 |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2013-05-03
- Last updated
- 2016-09-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01846481. Inclusion in this directory is not an endorsement.